Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc., a foreign private issuer, on January 29, 2016. The filing serves to distribute a news release regarding the company's scheduled presentation at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an informational notice regarding an upcoming event and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces a corporate event.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the presentation event. The filing does not contain updated guidance, outlook, risk factors, contingencies, or unusual items.
Key Facts for Investors to Verify
- The company is scheduled to present at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day.
- This filing contains no financial data; investors should refer to the company's most recent Form 40-F or quarterly reports for financial metrics.
- The filing was signed by Michael R. Martin, Chief Operating Officer.